HKBU and CUHK jointly develop new drug JCM-16021 for the treatment of Irritable Bowel Syndrome
05 Mar 2019
Researchers from Hong Kong Baptist University (HKBU) and the Chinese University of Hong Kong (CUHK) have developed a new formula, called JCM-16021, for the treatment of Irritable bowel syndrome (IBS). The novel drug will be subjected to a large-scale clinical trial with the aim of providing an additional effective therapy option for patients.
For more details, please visit: